Drug intelligence / Profile preview

CP-IL22BP mRNA

Development stage: Phase 1
Lead developer: West China Hospital of Sichuan University
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
Administration: Intratumoral

Overview

CP-IL22BP mRNA (Cationic Peptide-IL22BP mRNA) is an investigational mRNA-based immunogene therapy developed by West China Hospital of Sichuan University. The drug consists of mRNA encoding the Interleukin-22 Binding Protein (IL-22BP), a natural soluble inhibitory receptor that acts as an antagonist to Interleukin-22 (IL-22). IL-22 is a cytokine known to promote tumor progression and inflammation in various cancers; by delivering mRNA that expresses IL-22BP directly into the tumor, the therapy aims to neutralize IL-22 and inhibit tumor growth. The mRNA is delivered using a cationic peptide (CP) delivery system designed to facilitate intratumoral uptake. It is currently being evaluated in a Phase 1 clinical trial (NCT07040943) for patients with refractory advanced malignant solid tumors.

Other names: Cationic Peptide-IL22BP mRNA

Targets

IL22 (Interleukin 22)

Beyond the preview

Go deeper on CP-IL22BP mRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP-IL22BP mRNA.

Explore the full profile